Aradigm Corporation - Company & Market Research Reports

Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease. The company’s lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq (ARD-3150) and Lipoquin (ARD-3100) that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis and cystic fibrosis. Aradigm Corporation was founded in 1991 and is headquartered in Hayward, California.